Brief: Cabaletta Bio Q2 net income USD -14.487 million
10/08/2023 12:33
Aug 10 (Reuters) - Cabaletta Bio Q2 operating expenses USD 15.89 million. * Q2 net income USD -14.487 million * Q2 income from operations USD -15.89 million
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity